Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700202 · ClinicalTrials.gov registry record
Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 132
- Enrollment target
NCT04700202: Completed study, sponsored by Methodist Health System.
NCT04700202 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 132 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04700202 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 132 participants
- Enrollment target
Study Summary
Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
Primary Outcome
Percentage
Interventions
- OTHER Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2022-12-15 |
What the finished NCT04700202 record still lists
NCT04700202 is an observational study that tracks outcomes without assigning an intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT04700202 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04700202 about?
NCT04700202 is a clinical study titled "Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit". Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
What is the current status of trial NCT04700202?
This trial is currently completed. The enrollment target is 132 participants. The study started on 2020-06-30. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT04700202?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT04700202?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI